Background: Phosphatidylinositol 3′-hydroxyl kinase (PI 3-kinase) is activated by many growth factor receptors and is thought to exert its cellular functions through the elevation of phosphatidylinositol (3,4,5)-triphosphate levels in the cell. PI 3-kinase is required for growth-factor induced changes of the actin cytoskeleton which are mediated by the GTPases Rac and Rho. Recently, a role for Rac and Rho in regulating gene transcription has become evident.
Background
Stimulation of cells with a wide variety of agonists results in the activation of phosphatidylinositol 3′-hydroxyl kinase (PI 3-kinase) and a rapid elevation of the levels of phosphatidylinositol (3, 4, 5) -trisphosphate (PI(3,4,5)P 3 ) and phosphatidylinositol (3, 4) -bisphosphate (PI(3,4)P 2 ). PI 3-kinase is involved in cellular transformation or signalling by receptor and non-receptor tyrosine kinases in many cells. The form of PI 3-kinase implicated in these processes comprises a regulatory 85 kDa subunit containing two Src homology 2 (SH2) domains and (at its amino terminus) one SH3 domain, and a catalytic 110 kDa subunit [1, 2] . In response to extracellular stimuli, PI 3-kinase has been shown to associate physically with several signalling proteins, including growth factor receptors such as the platelet-derived growth factor (PDGF) receptor, non-receptor tyrosine kinases of the Src family, Abl or Crk [3] , and, more recently, GTP-binding proteins of the Ras and Rho families [4] [5] [6] .
Initial studies to identify the cellular functions of PI 3-kinase used mutant receptors whose phosphotyrosinebinding sites for PI 3-kinase were replaced with phenylalanine [7, 8] , or used a p85 mutant that lacked the p110-binding site [9, 10] . These mutants prevent the recruitment of PI 3-kinases into activated receptor complexes, but such dominant interfering approaches cannot distinguish between the requirement for two proteins that bind to the same site [11] . Additional tools for the study of PI 3-kinase effector pathways are inhibitors of PI 3-kinase function, such as wortmannin or the LY294002 compound, which compete for the lipid-or the ATP-binding sites on PI 3-kinase, respectively.
A recent advance in PI 3-kinase signalling studies has come from experiments with activated mutants generated by targeting the p110 catalytic subunit to the membrane. Studies comparing the effects of activating and interfering approaches have concluded that PI 3-kinase signals are necessary and sufficient for activation of p70 s6k [12] , a serine/threonine kinase, specific for ribosomal protein S6, which is required for cells to enter S phase after mitogen stimulation [13] . PI 3-kinase has also been shown to be required for activation of the extracellular signal-regulated kinase (ERK) pathway in several cell systems [14, 15] , although the expression of an activated PI 3-kinase does not seem to be sufficient for activation of the ERKs in mammalian cells [12] . These results demonstrate that PI 3-kinase can either function alone to initiate cellular responses or act in concert with other signalling pathways.
PI 3-kinase has also been shown, by the use of inhibitors, to be involved in the regulation of the actin cytoskeleton by growth factors such as PDGF or insulin [16] [17] [18] . Growth factors trigger membrane ruffling, and the subsequent formation of actin stress fibres, by a mechanism that is dependent on the function of the Rho family GTPases Rac and Rho, respectively [19] . The expression of constitutively active forms of these proteins, V12Rac and V14Rho, can mimic the responses induced by PDGF: V12Rac induces membrane ruffling and focal complex formation, and V14Rho induces actin stress fibres and focal adhesion assembly [19, 20] . The activation of PI 3-kinase is necessary for PDGF activation of Rac-and Rho-mediated rearrangements of the actin cytoskeleton [16, 17] ; indeed, previous studies have suggested that PI 3-kinase may regulate GTP-loading of Rac [21] and, hence, regulate Rho [17, 19] . It is unclear, however, whether PI 3-kinase activation is sufficient to induce Rac-and Rho-mediated cytoskeletal rearrangements or whether PI 3-kinase is a single component of more complex activation processes.
Comprehensive studies have recently established an additional role for Rac and Rho in mediating transcriptional regulation of the c-fos serum response element (SRE) [22] . The data concerning a role of PI 3-kinase in regulating SRE transcription has been controversial: some studies state that PI 3-kinase function is required for SRE induction [10, 15] , whereas others could not define a role for PI 3-kinase in this response [22] . Such discrepancies could be explained by the existence of parallel compensatory pathways. Information concerning the ability of active PI 3-kinase to generate positive signals that regulate Rac/ Rho transcription factor responses would thus be of value. A key question is whether PI 3-kinase is a general stimulator of Rac and Rho function in cells.
We investigated the ability of constitutively active PI 3-kinase to initiate Rac/Rho-mediated cytoskeletal rearrangements and Rac/Rho-mediated activation of transcription factor pathways. Our strategy to generate a constitutively active mutant was to localize subunits of PI 3-kinase to the membrane. Here, we show that membrane-targeting of the p110␣ catalytic subunit of PI 3-kinase generates a constitutively active enzyme that can induce actin reorganization, forming Rac-mediated membrane ruffles and focal complexes and Rho-mediated stress fibres and focal adhesions. However, expression of active PI 3-kinase did not induce Ras/Rac/Rho signalling pathways that can regulate transcription of c-fos, c-fos SRE, or the transcription factors AP-1 or Elk-1. Hence, PI 3-kinase induces a selective subset of cellular responses but is not sufficient to stimulate the full range of Rac-or Rhomediated responses.
Results

Construction and biochemical characterization of membrane-targeted rCD2-PI 3-kinase chimeras
To localize PI 3-kinase at the membrane, we constructed chimeric molecules in which the cytoplasmic domain of the rat CD2 (rCD2) cell-surface antigen was replaced with either subunit of PI 3-kinase (Fig. 1a) : the extracellular and transmembrane domains of the rCD2 antigen were linked to the amino terminus of p85␣ (rCD2p85) or p110␣ (rCD2p110). As a control, a rCD2p110 construct with an inactivating point mutation (the arginine at position 1130 replaced with a proline; R1130P) in the ATP-binding site [23] , which abolishes its kinase activity (rCD2p110-R/P), was generated. These fusion proteins were transiently expressed in Cos7 cells, and western-blot analysis of the resulting protein chimeras with rCD2 monoclonal antibodies revealed the presence of molecular species of the predicted masses (Fig. 1b) . Cell-surface expression of the different rCD2-PI 3-kinase chimeras was confirmed by flow cytometric immunofluorescence analysis with an anti-rCD2 monoclonal antibody (Fig. 1c) .
To assess whether rCD2-PI 3-kinase chimeras had lipid kinase activity, the chimeras were immunoprecipitated with an anti-rCD2 monoclonal antibody and subjected to PI kinase assays in vitro. rCD2p110 had strong PI 3-kinase activity in vitro, which was dependent on the integrity of the p110 ATP-binding site -there was no detectable lipid kinase activity in comparable immunocomplexes of rCD2p110-R/P (Fig. 1d) . These results show that the fusion of p110 to the rCD2 extracellular and transmembrane domains does not adversely affect the folding of the protein and thus destroy the catalytic activity of the enzyme. There was also low-level PI kinase activity associated with the rCD2p85 chimera. Western-blot analysis confirmed that this reflected an association of rCD2p85 with the endogenous p110␣ catalytic subunit of PI 3-kinase (data not shown).
To explore the effect of membrane recruitment of the PI 3-kinase subunits on cellular levels of D-3 phosphorylated inositol lipids in intact cells, Cos7 cells were transiently transfected with expression vectors for the different rCD2-PI 3-kinase chimeras. The cells were metabolically labelled with [ 32 P]orthophosphate, the phospholipids were extracted, and the levels of D-3 phosphorylated phosphoinositides were determined (Fig. 1e) . Strikingly, expression of rCD2p110 caused a four-fold increase in PI(3,4)P 2 levels and approximately a six-fold elevation of PI(3,4,5)P 3 levels compared with basal levels in control cells. The stimulatory effects of rCD2p110 were due to the catalytic activity of the membrane-bound p110 protein -expression of equivalent levels of the rCD2p110-R/P mutant did not alter levels of PI(3,4)P 2 and PI(3,4,5)P 3 . Similarly, expression of rCD2p85 did not increase cellular levels of PI(3,4)P 2 or PI(3,4,5)P 3 (Fig. 1e) . We conclude that plasma membranetargeting of the p110 catalytic subunit generates a mutant that is constitutively active in vivo, whereas membrane-targeting of the p85 regulatory subunit has no effect on the levels of D-3 phosphorylated inositol lipids in vivo. Immunocomplexes of rCD2p85 contained PI 3-kinase activity in vitro as this chimera formed an association with endogenous PI 3-kinase catalytic subunits (Fig. 1d) . The level of activity in these complexes was extremely low in comparison to the activity in immunocomplexes containing rCD2p110, explaining the failure of rCD2p85 to regulate endogenous levels of D-3 phosphoinositides.
Recent studies have shown that membrane-targeting of the PI 3-kinase catalytic subunit using a CAAX motif generates a constitutively active enzyme that activates the serine/threonine kinases PKB and p70 s6k [12] , which play a critical role in the regulation of protein translation and cell-cycle progression [13] . rCD2p110, but not rCD2p85 or rCD2p110-R/P, was able to fully replace serum for activation of PKB and p70 s6k (data not shown). In contrast, rCD2p110 did not activate the mitogen-activated protein (MAP) kinase ERK1 (data not shown), in agreement with recent studies showing that PI 3-kinase is Research Paper PI 3-kinase effector pathways Reif et al. 1447
Figure 1
Construction and characterization of membrane-targeted rCD2-PI 3-kinase chimeras. (a) Schematic of the rCD2-PI 3-kinase chimeras. Numbers correspond to amino acids in the protein and demarcate the extracellular, transmembrane, and cytoplasmic domains. Amino acid 216 depicts the start of the wild-type p85␣ or p110␣ molecules. The location of the kinase domain (green box) and the inactivating point mutation R1130P (black dot) are denoted. rCD2p110 and rCD2p110-R/P contain a carboxy-terminal myc tag (triangle). (b) Western-blot analysis of cell lysates from Cos7 cells transiently transfected with 10 g of expression vectors encoding rCD2p85, rCD2p110, or rCD2p110-R/P, using anti-rCD2 (Ox34) monoclonal antibodies. (c) Flow cytometry of Cos7 cells, from (b), expressing rCD2p85, rCD2p110 and rCD2p110-R/P stained with anti-rCD2 monoclonal antibodies followed by fluoresceinconjugated anti-mouse antibody (shaded in black). As a control, each population of transfected cells was incubated with mouse IgG as primary antibody (shaded in grey). (d) PI kinase activity present in anti-rCD2 immunoprecipitates. Cos7 cells were transiently transfected with 10 g of empty vector (control), or expression vectors encoding rCD2p85, rCD2p110 or rCD2p110-R/P, as indicated. Immunoprecipitations and PI kinase assays were performed as described in Materials and methods. [ 32 P]phosphate incorporation into PI (see inset) was quantified using a PhosphorImager and is expressed as fmol of [ 32 P]PIP per min. The expression levels of rCD2-PI 3-kinase chimeras in anti-rCD2 immunoprecipitates were assessed in parallel by western-blot analysis using anti-rCD2 monoclonal antibodies. Expression levels of rCD2p110 and rCD2p110-R/P were equal; rCD2p85 expression levels were about 3-fold higher than those of rCD2p110 or rCD2p110-R/P, as quantitated by scanning of protein band intensities from the autoradiograph and densitometry analysis. (e) Elevation of PI(3,4)P 2 and PI(3,4,5)P 3 levels in intact Cos7 cells by expression of rCD2p110. Cos7 cells were transfected with 5 g plasmid DNA encoding the indicated constructs, labelled with [ 32 P]orthophosphate, and the levels of PI(3,4)P 2 and PI(3,4,5)P 3 were determined. The data is expressed as fold induction of basal levels of PI(3,4)P 2 and PI(3,4,5)P 3 in control cells. Data were normalized to PI(4,5)P 2 levels in each dish. In control cells, the values of each polyphosphoinositide were: PI(4,5)P 2 , 2 157 362 cpm; PI(3,4)P 2 , 6 821 cpm; PI(3,4,5)P 3 , 1 699 cpm. The fold inductions for rCD2p110 in three independent experiments were: for PI(3,4)P 2 : 4.2-, 4.4-and 14.5-fold; and for PI(3,4,5)P 3 : 5.8-, 8.6-and 3.4-fold. Expression of rCD2-PI 3-kinase chimeras was checked in parallel by westernblot analysis using an anti-rCD2 monoclonal antibody. PIP not sufficient to activate the ERKs in mammalian cells [12] . These data indicate that membrane-localized rCD2p110 is an effective tool to investigate the cellular functions of PI 3-kinase.
Expression of active PI 3-kinase leads to membrane ruffling and stress fibre formation in Swiss 3T3 cells
Cytoskeletal responses triggered by PDGF require PI 3-kinase activation [16, 17] . We used membrane-bound rCD2p110 to determine whether PI 3-kinase signals were sufficient to trigger Rac/Rho cytoskeletal signalling pathways. Serum-starved subconfluent Swiss 3T3 cells were microinjected with an expression vector encoding the active PI 3-kinase rCD2p110, and the pattern of filamentous actin distribution was assessed by immunofluorescence in cells expressing rCD2p110 proteins (Fig. 2) . Four hours after injection, polymerized actin was seen to form localized lamellipodia around the cell margin and, moreover, to form actin stress fibres (Fig. 2a) . These results were confirmed by time-lapse image recording where subconfluent cells expressing rCD2p110 showed active membrane ruffling (data not shown). Swiss 3T3 cells expressing rCD2p110 also exhibited a polarized cell shape ( Fig. 2a,b ). To analyze these cytoskeletal rearrangements further, quiescent cells were stained for vinculin distribution, which monitors the formation of Rac-dependent focal complexes and Rho-dependent focal adhesions [24] .
In cells expressing the active PI 3-kinase, vinculin could be found localized in discrete punctuate spots around the cell margin forming focal complexes and focal adhesions in the body of the cell (Fig. 2b) . Control cells expressing the inactive rCD2p110-R/P chimera did not show these structures (Fig. 2c,d ). The changes in cell morphology triggered by V12Rac and rCD2p110 were qualitatively the same (compare Fig. 2a ,b with 2e,f), although V12Rac induced the formation of vinculin spots uniformly around the entire periphery of the cell (Fig. 2f) , whereas the effects of rCD2p110 were localized to discrete areas of the plasma membrane (Fig. 2b ).
Cytoskeletal rearrangements induced by PI 3-kinase are dependent on endogenous Rac and Rho function
Membrane ruffling and focal complex formation induced by rCD2p110 were similar to those described for activators of Rac, whereas the effects of rCD2p110 on actin stress fibres and focal adhesion assembly were identical to those described for activators of Rho [19, 24] . To assess directly the role of Rac and Rho in PI 3-kinase-mediated cytoskeletal responses, we used N17Rac, a dominant inhibitory mutant of Rac that prevents activation of endogenous Rac [19] . To inhibit endogenous Rho function, cells were microinjected with Clostridium botulinum C3 transferase, which ADP-ribosylates and inactivates Rho [19] . The microinjection of N17Rac proteins abolished membrane ruffles and stress fibre formation in cells expressing active rCD2p110 (Fig. 2e , compare the right-hand cell with the left-hand cell). Hence, cytoskeletal rearrangements triggered by active PI 3-kinase are dependent on the function of Rac proteins. Expression of C. botulinum C3 transferase inhibited rCD2p110-induced assembly of actin stress fibres but not the increase in filamentous actin forming membrane ruffles (Fig. 2f) . Strikingly, in cells where Rho function was blocked, the active PI 3-kinase induced a pattern of vinculin staining indistinguishable from that seen in cells expressing activated V12Rac (compare Fig. 2g with 2h): focal complexes around the cell margin, but no vinculin aggregation indicative of Rho-mediated focal adhesions, could be detected (compare Fig. 2g with 2b) . Collectively, these data show that PI 3-kinase can stimulate both Rac-dependent pathways for the formation of focal complexes and membrane ruffling, and Rac/Rho pathways that induce stress fibre and focal adhesion assembly.
rCD2p110 does not induce SRE-, c-fos-, or Elk-1-dependent gene expression
An additional function for the GTPases Rac and Rho has been demonstrated recently: to regulate the transcriptional activity of the c-fos serum response factor (SRF) [22] . We therefore examined whether PI 3-kinase is a universal regulator of Rac-and Rho-function by assessing the ability of rCD2p110 to induce changes in transcriptional activity of the c-fos SRE. In these experiments, we investigated cellular responses to the expression of constitutively active mutants of Rac and Rho, and to regulators of endogenous Rho signalling pathways: serum and Dbl [25] , a guanine nucleotide exchange protein that regulates Rho family GTPases. SRE activity was monitored with a SRE-CAT (chloramphenicol acetyl transferase) reporter gene, which is known to be the target of a signalling cascade initiated by the GTPases Cdc42, Rac and Rho [22] . Accordingly, expression of V14Rho or V12Rac stimulated the expression of the SRE-CAT reporter gene to a level equivalent to the response induced by serum (Fig.  3a) . However, no SRE-CAT induction could be observed in cells expressing the constitutively active PI 3-kinase alone or in conjunction with suboptimal levels of serum. Furthermore, expression of rCD2p110 alone did not stimulate c-fos promoter activity (Fig. 3c) , nor could it synergize with serum for this response (data not shown). The expression of Dbl induced SRE activity (Fig. 3b) , but SRE responses triggered by the expression of Dbl or serum were prevented by co-expression of C3 transferase, indicating that SRE regulation by these stimuli is mediated by endogenous Rho signalling pathways. Thus, transcriptional activation of the SRE can be regulated by signalling pathways initiated by serum or by Dbl and mediated by the GTPase Rho, but these responses cannot be induced by a constitutively active PI 3-kinase.
Transcriptional activation from the SRE requires SRF binding. At the c-fos SRE, SRF forms a ternary complex with TCF (ternary complex factor), which cannot bind the SRE by itself. One member of the TCF is Elk-1, which is a substrate for both MAP kinase families, the ERKs [22, 26] and the stress-activated protein (SAP) kinase (also known as c-jun N-terminal kinase; SAPK or JNK) [27] [28] [29] . As Rac has been shown to be involved in regulating the JNK/SAPK signalling pathway [30, 31] , we investigated whether activated rCD2p110 could induce Elk-1 activation. To monitor Elk-1 transcriptional activity, a fusion protein comprising the carboxyl terminus of Elk-1 linked to the LexA repressor [32] was co-transfected into NIH 3T3 cells with a LexA operator-controlled CAT reporter gene. LexA-Elk-1 transcriptional activity was low in quiescent fibroblasts, but could be induced by co-expression of active Ha-v-ras, by stimulation with serum, or by UV irradiation (Fig. 3d) . However, expression of rCD2p110 did not stimulate Elk-1 activity (Fig. 3d) , indicating that a constitutively active PI 3-kinase cannot stimulate the UV-activated stress kinase JNK. This observation was confirmed by direct kinase assays of JNK in vitro (data not shown).
Expression of the Fos protein is required for the promoter activity of many genes. Fos is a component of the AP-1 complex, and hence increased cellular levels of Fos proteins can be monitored by assessing whether the activity of the transcription factor AP-1 becomes upregulated. The AP-1 complex also contains the transcription factors c-Jun and ATF2, and is a target for members of both MAP kinase families, SAPKs and Erks, and their upstream regulators of the Ras and Rho family of GTPases. We determined the ability of activated Ras and activated PI 3-kinase to induce transcriptional activity of AP-1 complexes: Ha-v-ras led to expression of an AP-1-CAT reporter gene and synergized with serum for optimal induction of AP-1-CAT (Fig. 3e) 
Discussion
A chimeric molecule in which the cytoplasmic domain of the rCD2 cell-surface antigen was replaced with the p110␣ subunit of PI 3-kinase allows plasma-membrane localization of the catalytic subunit of PI 3-kinase. The membrane-bound rCD2p110 induces accumulation of cellular levels of PI(3,4)P 2 and PI(3,4,5)P 3 equivalent to those seen after mitogenic stimuli: in cells transiently transfected with rCD2p110, there is an approximate fivefold increase in cellular levels of PI(3,4,5)P 3 . As shown in Figure 1c , 15-20 % of the total population of transiently transfected Cos7 cells express the rCD2p110 chimeras. When normalized to the transfection efficiency, this gives an increase in PI(3,4,5)P 3 levels in cells expressing rCD2p110 of approximately 25-30-fold -well within the range described for growth-factor induced elevations of cellular levels of PI(3,4,5)P 3 . That the rCD2p110 fusion protein is a useful tool for the investigation of the cellular responses triggered by PI 3-kinase was confirmed in coexpression studies: rCD2p110 activated PKB/Akt and p70 s6k but not the ERKs (data not shown).
Here, we show that PI 3-kinase signals are sufficient to induce cytoskeletal changes that include actin polymerization, resulting in Rac-mediated formation of membrane lamellipodia and focal adhesions and Rho-induced formation of actin stress fibres and focal complexes. Moreover, we show that endogenous Rho and Rac functions are required for these processes, respectively. It is now recognized that Rho family GTPases play an important role in the activation of transcription factors and hence are contributing to the regulation of cell growth. The ability of PI 3-kinase signals to initiate the Rac/Rho-mediated responses in the context of the actin cytoskeleton raises the issue of whether PI 3-kinase is a universal activator of Rac/Rho signal transduction pathways. The present data show that expression of constitutively active PI 3-kinase cannot induce Ras/Rac/Rho signalling pathways that regulate gene transcription from SRE, c-fos, Elk-1 or AP-1 reporters. PI 3-kinase signals also could not synergize with serum to induce gene expression from these CAT reporters. In contrast, activation of endogenous GTPases with serum or by expression of Dbl could activate Rhomediated stress fibre formation [33] and Rho-mediated SRE transcriptional activation (Fig. 3b) . Similarly, studies have shown that Dbl can induce Rac-mediated actin cytoskeleton responses and Rac-mediated JNK/SAPK activation [30, 31] . Our results demonstrate that PI 3-kinase induces a selective subset of cellular responses but is not sufficient to stimulate the full range of Rac-or Rhocoordinated pathways. PI 3-kinase is therefore not a universal activator of Rac/Rho-mediated signalling cascades. To explain this phenomenon, it is necessary to evoke discrete subpopulations of these GTPases that are linked to different upstream regulatory proteins and diverse effector pathways. The existence of diverse effector molecules for Rac and Rho has been established, mainly by studies of proteins that interact with Rac and Rho: the p21-associated kinase (Pak1) binds to and is activated by GTPbound Rac or Cdc42 [34] . A different novel target of Rac, POR1, may link Rac to cellular responses controlling membrane ruffling [35] . Similarly, two different protein kinases, PKN [36, 37] and p164 Rho kinase (ROK) [38, 39] associate with active Rho. ROK may act as the Rho effector controlling stress fibre formation by inhibiting myosin light-chain phosphatase [40, 41] , but its role in coupling Rho to the regulation of transcription factors is unclear.
The present study suggests that different Rac and Rho effectors are not necessarily coordinately activated and may be triggered by distinct intracellular signalling pathways. Hence, PI 3-kinase signals can induce Rac/Rho-mediated cytoskeletal changes without activating Rac/Rho-mediated transcription factor pathways. Expression of Dbl activates a wider repertoire of Rac/Rho cellular responses than the membrane-targeted PI 3-kinase. These observations could be explained by several models, described below, which imply spatial restrictions of Rac/effector complexes. In a simplistic model, the failure of PI 3-kinase-activated Rac to interact with the full range of Rac effector molecules could result from subcellular compartmentalization of different pools of these proteins. For example, pool 1 of Rac/Rho effectors involved in cytoskeletal rearrangements could be constitutively membrane-localized: receptor activation of PI 3-kinase will generate D-3 phosphoinositides in the plasma membrane, which would spatially restrict the regulatory capacity of these lipids to only membranelocalized pools of Rac/Rho effectors. The expression of oncogenic Dbl is not confined to the plasma membrane and Dbl would come into contact with both pools of Rac/effector complexes, including pool 2, which has a more cytoplasmic distribution and transduces transcriptional activation. The discrepancy between the functional effects of Dbl and active PI 3-kinase could then be explained by their different cellular localization. Evidence from a recent study supports this type of model: the pleckstrin homology (PH) domain of Dbl targets the protein to specific cytoskeletal locations, and a plasma membranetargeted Dbl with a truncated PH domain is not fully active [42] .
A second spatial model, in which pool 2 of effector proteins are actively recruited, allows for the potential of additional signals derived from growth factors (spatial model 2; Fig. 4a ). Such signals would recruit different pools of Rac effector molecules into the proximity of Rac activated by PI 3-kinase. Hence, PI 3-kinase signals may be able to cooperate with other signals generated from growth factors to allow full induction of Rac/Rho-mediated signalling pathways, in particular the activation of transcription factor responses. In this context, a recent report describes that the adaptor protein Nck binds to the Rac effector kinase Pak1 [43] ; this result is consistent with a mechanism that recruits Pak1 into activated growthfactor receptor complexes and hence to sites in the membrane containing Rac activated by PI 3-kinase. Whether this is the case remains to be elucidated, yet PI 3-kinase signals did not concur with serum-derived signals to give activation of gene expression. Therefore, an alternative model to activate Rac/Rho-mediated gene transcription may involve an independent, as yet uncharacterized, mechanism that does not involve PI 3-kinaseautonomous regulation of pool 2 of effector proteins (spatial model 3; Fig. 4b ).
The identity of the direct targets for D-3 phosphoinositides that regulate the activation of Rac and Rho is currently unknown. The activity of Rho family GTPases is controlled by the concerted action of guanine nucleotide exchange factors (GEFs), guanine nucleotide dissociation inhibitors (GDIs) and GTPase activating proteins (GAPs). Which of these will be targeted by D3 phosphoinositides is not clear but it is tempting to speculate that PH domains, which have been shown to bind phosphoinositollipids and are present in Rho family GEFs, could provide the link between lipid kinases and Rac/Rho. However, any model for regulation of Rho family GTPases must include a mechanism to explain how growth factors apparently have the ability to activate Rac and Rho by mechanisms autonomous of PI 3-kinase. For example, the lysophosphatidic acid (LPA) receptor can bypass PI 3-kinase and Rac to stimulate Rho-dependent responses by a different route. Finally, as demonstrated by the present report, models for activation of Rac and Rho must be superimposed by models that allow for selective activation of different Rac/Rho effectors by diverse regulatory proteins with the subsequent stimulation of divergent cellular responses.
Conclusions
Rho family GTPases have been shown to be important for the regulation of different cellular responses, including gene transcription, the activation of certain members of the MAP kinase family, and changes in the actin cytoskeleton. Although it is becoming evident that these diverse cellular responses are mediated by different effector proteins that associate with the activated GTPase complexes, little is known of how growth factor receptors orchestrate these distinct effector pathways, in particular whether triggering of the receptor will uniformly activate all cellular pathways mediated by a certain GTPase. PI 3-kinase is activated by many growth factor receptors, leading to an increase in D-3 phosphoinositides in the plasma membrane. PI 3-kinase-derived signals are sufficient to induce growth factor-like changes of the actin cytoskeleton mediated by the GTPases Rac and Rho, but are not sufficient to stimulate Rac/Rho-mediated gene transcription. Hence, PI 3-kinase activates a distinct subset of Rac/Rho effector pathways but does not give the full repertoire of GTPase responses. Our data suggest, therefore, that it is possible to selectively activate different GTPase effector pathways. We propose that specific subcellular compartmentalization mechanisms exist that localize different exchange factor/GTPase complexes to divergent downstream effector pathways.
Materials and methods
Construction of chimeric cDNAs
The coding regions of bovine p85␣ [44] and p110␣ [2] were attached to a truncated rat CD2 molecule consisting of the extracellular and transmembrane domain (EMBL accession number X05111; [45] ). The rCD2 intracellular domain was truncated at the stop transfer sequence (amino acids 1-212) by the addition of a NotI site. The p85␣ and p110␣ subunits were adapted with a NotI site at the 5′ end omitting the methionine of the leader sequence and introducing the peptide SGR in the coding sequence at the hinge. The NotI-p110 construct was tagged at the carboxyl terminus with the Myc epitope [46] . To construct the inactive rCD2p110-R/P, a 533 bp PstI-NcoI cartridge from NotI-p110 was replaced with the corresponding cartridge from the described p110-BamHI plasmid containing the R916P mutation [23] . The rCD2-PI 3-kinase chimeras were assembled by subcloning the mutated cDNAs into the pcDNA3 vector (Invitrogen) (Fig. 1) or a human cytomegalovirus (CMV) promoter-driven expression vector [47] (Figs 2,3 ). All obtained constructs were verified by nucleotide sequencing and/or restriction enzyme analysis.
Plasmids and reporter constructs
Ha-v-ras [48] , V14Rho, V12Rac and C3 transferase [22] vector constructs have been described. For the microinjection experiments, 
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V12Rac was expressed as myc-tagged derivative from the CMV promoter-driven vector (see above 
Western-blot analysis
Transfected Cos7 cells were washed with PBSA and lysed in 0.5 ml Cos7 lysis buffer (1 % (w/v) Triton X-100, 20 mM Tris pH 7.5, 137 mM NaCl, 15 % (v/v) glycerol, 2 mM EDTA, 2 mM PMSF, 20 g ml -1 aprotinin, 2 mM benzamidine, 1 mM sodium orthovanadate, and 2 g ml -1 of the small peptide inhibitors leupeptin, pepstatin A and chymostatin).
Western-blot analysis of total postnuclear cell lysates or immunoprecipitates was performed as described [52] using Ox34 monoclonal antibody raised against rCD2 [45] .
Immunoprecipitation of rCD2-PI 3-kinase chimeras and PI kinase assays
Transfected Cos7 cells were washed with PBSA and lysed in 0.5 ml Cos7 lysis buffer (see above). Postnuclear lysates were precleared with protein A cell suspension (Sigma) prior to precipitation with antirCD2 monoclonal antibody and rabbit anti-mouse IgG (DAKO) precoupled to protein A-Sepharose beads (Sigma). When PI kinase assays were performed the immunoprecipitates were washed once in Cos7 lysis buffer, twice in washing buffer 1 (100 mM Tris pH 7.5, 0.5 M LiCl and 100 M sodium orthovanadate) and twice in washing buffer 2 (50 mM Hepes pH 7.4, 100 mM NaCl, 1 mM EDTA and 100 M sodium orthovanadate). The washed immunoprecipitates were resuspended in 10 l lipid mixture (1 mg ml -1 each L-␣-phosphatidylinositol and L-␣-phosphatidyl-L-serine, dispersed by sonication in 25 mM Hepes pH 7.4 and 1 mM EDTA). The reaction was initiated by the addition of 40 l PI-kinase reaction buffer (containing 100 nM [␥-32 P]ATP (10 Ci), 125 M ATP, 12.5 mM MgCl 2 , 125 mM NaCl, 25 mM Hepes pH 7.4 and 250 M adenosine). After 15 min at 25°C, the reaction was terminated and the samples processed as described [52] . Incorporation of 32 P into PI was quantified using a PhosphorImager (Molecular Dynamics). The [ 32 P]PIP counts obtained for each sample were normalized to the specific activity of the [␥-32 P]ATP used for the assay, and are expressed as fmol of PIP per min.
HPLC analysis of inositol phosphates
Phospholipid extractions were based on the method described previously [53] . Briefly, cells were washed with PBSA, collected in 1 ml 2.4 M HCl and transferred to a polypropylene test tube. CHCl 3 :MeOH (1:2 v/v) (1.5 ml) containing 10 g phosphoinositides (Sigma) to act as carrier lipids were added followed by 1 ml CHCl 3 . After vortexing and centrifugation the lower phase was removed to a fresh tube, the upper phase was re-extracted twice with 1.5 ml of CHCl 3 and the CHCl 3 phases were combined. Dry lipid films were deacylated with 0.5 ml methylamine at 50 °C for 1 h in the presence of 50 l n-butanol. The resulting glycerophosphoinositol esters were re-dissolved in 0.5 ml water and extracted once with an equal volume of n-butanol. The aqueous phase was mixed with 3 H-labelled IP 4 (Du Pont) as an internal standard [54] and resolved by anion-exchange on HPLC using a S5 SAX column (Phase Separations). The column was eluted at 1 ml min -1 with a linear gradient of Milli Q water versus 2.5 M NaH 2 PO 4 (pH 3.8 with NaOH (% B)); times were t = 0, % B = 0; t = 10, % B = 0; t = 60, % B = 12; t = 70, % B = 19; t = 110, % B = 50, t = 130, % B = 50; t = 140, % B = 0; fractions were collected every 0.5 min. The data are collected as values of 32 P and 3 H radioactivity measured using a calibrated 3 H/ 32 P dual-label program on a Beckman LS6000 series scintillation counter.
Microinjection experiments
Serum-starved sub-confluent Swiss 3T3 cells were prepared for microinjection as described [55] . Plasmid DNAs were microinjected at 200 g ml -1 in PBS into the nucleus. After 3-4 h, cells were fixed with 4 % paraformaldehyde (w/v). To prevent activation of endogenous Rac and Rho proteins, rCD2p110 microinjected cells were re-injected with recombinant N17Rac proteins (0.7 mg ml -1 ) and C3 transferase (100 g ml -1 ), respectively, and after 30 min cells were fixed. Vinculin or actin was visualized by immunofluorescence, essentially as described [55] . Briefly, permeabilized cells were double-labelled for actin and protein expression by first incubating with Ox34 monoclonal antibody to detect rCD2-PI 3-kinase chimeras. Then cells were incubated with FITC-conjugated goat anti-mouse antibody, and for detection of actin, with rhodamine-phalloidin (0.1 g ml -1 ). For re-injection experiments, recombinant proteins were co-injected together with rat IgG (0.5 mg ml -1 ) as an injection marker which was visualized using a cascade blue-conjugated goat anti-rat IgG. For vinculin-staining cells were co-injected with Texas Red-lysinated dextran (2 mg ml -1 ) as an injection marker. Vinculin was localized as described [55] . Recombinant N17Rac proteins and C3 transferase were prepared as described [19] .
Gene expression analysis
8-10 h after inductions as indicated, transfected serum-starved NIH 3T3 cells were washed with PBSA and cells were lysed in 150l lysis buffer (0.65 % Triton-X100, 10 mM Tris pH 8, 1 mM EDTA and 150 mM NaCl). Gene expression assays were carried out essentially as described [56] .
The following amounts of plasmid were used: rCD2p110 (0.5g), rCD2p110-R/P (0.5 g), V14Rho (1 g), V12Rac (1 g), Dbl (1 g) or C3 transferase (2 g). 4 g of CAT reporter constructs and 0.25 g of pMLVNlex.elk-1 were used. Transfection efficiency was monitored with appropriate ␤-galactosidase (lacZ) expression vectors (used at 1 g) as described [57] . The data are presented as the ratio of CAT activity (percentage conversion) to ␤-galactosidase optical density (OD) units.
Other methods
Cos7 cells were subjected to immunofluorescent staining and flow cytometry using the Ox34 monoclonal antibody and for control staining mouse IgG (Sigma) followed by FITC-conjugated rabbit anti-mouse IgG (DAKO) employing standard protocols.
